Predictive factors of response toIVIGin pediatric immune thrombocytopenic purpura

Authors:

Abstract
Background: Immune thrombocytopenic purpura (ITP) is commonly treated with i.v. immunoglobulin (IVIG).Methods: We retrospectively evaluated whether pretreatment clinical and laboratory finding could predict the short‐ and long‐term response toIVIG.Results: Short‐term response was estimated by platelet count 2 weeks afterIVIG, and long‐term response was assessed on thrombocytopenia‐free survival (TFS).TFSwas defined as the probability of survival without treatment failure after initialIVIG, such as relapse, requirement for additional therapeutic interventions, or progressing to chronicITP. Seventy‐six patients with newly diagnosedITPwho were initially treated withIVIGwere evaluated. Fifty‐three patients (69.7%) were determined as responders at 2 weeks afterIVIG. On multivariate analysis, age ≥23 months (P= 0.020) and platelet count 9/L (P= 0.018) were considered to be unfavorable factors for short‐term response. Cumulative proportion of long‐term (1 year) good prognosis was estimated at 53.0% (95%CI: 40.8–65.2). On multivariate analysis of unfavorable factors for long‐term response, age ≥23 months (P= 0.020) was the only significant factor.Conclusions: For new‐onsetITPin patients aged >2 years, corticosteroid therapy in addition toIVIGmay be considered as the initial treatment.

This publication has 12 references indexed in Scilit: